Clinical Social Workers in Arcadia, WI Accepting Medicare
4 Clinical Social Workers found. Showing 1 - 4
 Kim M Davis-rislove, MSSW LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 895 Dettloff Dr, Arcadia, WI 54612 Phone: 608-785-0940 |
 David E Brown, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 895 Dettloff Dr, Arcadia, WI 54612 Phone: 608-785-0940 |
Janet W Butler, MSSW LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 895 Dettloff Dr, Arcadia, WI 54612 Phone: 608-785-0940 |
David R Lewis, MSSW, LICSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 464 S Saint Joseph Ave, Arcadia, WI 54612 Phone: 608-323-3210 |
News Archive
Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has met with the FDA regarding it's supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for injection for the treatment of patients with advanced metastatic colorectal cancer. In October 2009, the FDA issued a Complete Response letter regarding its sNDA for FUSILEV.
CDC: Baby boomers should be tested for Hep C
Americans born between 1945 and 1965 are at particularly high risk for Hepatitis C and should be tested, according to new recommendations from the Centers for Disease Control and Prevention.
Oxygen' common stock to begin trading on Swiss SIX Exchange
Oxygen Biotherapeutics, Inc. announced today that the company's common stock will begin trading on the Swiss SIX Exchange with the opening of trading tomorrow, Tuesday, June 29, 2010. The company's shares will trade under the same ticker symbol, OXBT, as they currently do on the NASDAQ Capital Market.
Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The study is aimed at evaluating the safety and tolerability of ALN-TTR02 in healthy volunteers.
› Verified 3 days ago